NasdaqGM - Nasdaq Real Time Price USD

CureVac N.V. (CVAC)

3.4700
-0.1200
(-3.34%)
At close: May 9 at 4:00:00 PM EDT
3.4700
0.00
(0.00%)
After hours: May 9 at 4:05:10 PM EDT
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
535,180
535,180
53,758
67,420
102,990
Cost of Revenue
105,829
105,829
124,366
183,993
238,195
Gross Profit
429,351
429,351
-70,608
-116,573
-135,205
Operating Expense
251,669
251,669
203,599
132,884
277,058
Operating Income
177,682
177,682
-274,207
-249,457
-412,263
Net Non Operating Interest Income Expense
12,357
12,357
15,448
-567
-235
Other Income Expense
842
842
-1,210
869
--
Pretax Income
190,881
190,881
-259,969
-249,155
-412,498
Tax Provision
28,695
28,695
198
-126
-782
Net Income Common Stockholders
162,186
162,186
-260,167
-249,029
-411,716
Diluted NI Available to Com Stockholders
162,186
162,186
-260,167
-249,029
-411,716
Basic EPS
0.48
0.72
-1.18
-1.32
-2.21
Diluted EPS
0.47
0.72
-1.18
-1.32
-2.21
Basic Average Shares
224,229.6780
224,376.8300
220,910.5090
189,074.9110
186,012.5860
Diluted Average Shares
225,032.3840
225,270.4540
220,910.5090
189,074.9110
186,012.5860
Total Operating Income as Reported
177,682
177,682
-274,207
-249,457
-412,263
Total Expenses
357,498
357,498
327,965
316,877
515,253
Net Income from Continuing & Discontinued Operation
162,186
162,186
-260,167
-249,029
-411,716
Normalized Income
161,470.5772
161,470.5772
-259,259.5000
-249,897.5605
-411,716
Interest Income
12,357
12,357
15,411
1,733
10,103
Interest Expense
0
0
0
2,299
10,338
Net Interest Income
12,357
12,357
15,448
-567
-235
EBIT
190,881
190,881
-259,969
-246,856
-402,160
EBITDA
209,690
209,690
-236,583
-223,115
-386,486
Reconciled Cost of Revenue
94,834
94,834
114,801
171,612
231,502
Reconciled Depreciation
18,809
18,809
23,386
23,741
15,674
Net Income from Continuing Operation Net Minority Interest
162,186
162,186
-260,167
-249,029
-411,716
Total Unusual Items Excluding Goodwill
842
842
-1,210
869
0
Total Unusual Items
842
842
-1,210
869
0
Normalized EBITDA
208,848
208,848
-235,373
-223,984
-386,486
Tax Rate for Calcs
0.0002
0.0002
0.0003
0
0
Tax Effect of Unusual Items
126.5772
126.5772
-302.5000
0.4395
0
12/31/2021 - 8/14/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ARCT Arcturus Therapeutics Holdings Inc.
10.98
-3.51%
 
BNTX BioNTech SE
92.77
-2.12%
 
22UA.DE BioNTech SE
83.35
-0.71%
 
PBYI Puma Biotechnology, Inc.
2.9100
-5.21%
 
ABUS Arbutus Biopharma Corporation
3.2300
-2.12%
 
VXRT Vaxart, Inc.
0.4196
+3.10%
 
PDSB PDS Biotechnology Corporation
1.2000
-1.64%
 
DSGN Design Therapeutics, Inc.
3.5000
-0.57%
 
FULC Fulcrum Therapeutics, Inc.
5.37
-0.74%
 
VIR Vir Biotechnology, Inc.
5.09
-6.01%